Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
Paraneoplastic pemphigus (PNP) is an autoimmune blistering disease that presents as severe mucosal erosions and variable cutaneous lesions and is primarily associated with hematologically malignant or benign diseases. A 59-year-old Japanese woman presented with oral, ocular and vaginal mucosal erosions and erythema as well as blistering on her trunk and limbs. She developed bronchiolitis obliterans; lymphadenopathy in the cervical, subclavian, para-aortic and intraperitoneal regions; and splenomegaly. PNP with B-cell lymphoma was diagnosed. She was treated with two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) for B-cell lymphoma, rituximab once every 3 weeks for five cycles, steroid pulse therapy, oral prednisolone, cyclosporin and high-dose i.v. immunoglobulin. The B-cell lymphoma was in remission after two courses of R-CHOP treatment. Although her skin erythema and blistering were also improved, the mucosal erosions and bronchiolitis obliterans gradually worsened. The patient died of bronchiolitis obliterans after 6 months of hospitalization. Because a cellular immune response is thought to be involved in the pathogenesis of PNP, cyclosporin therapy is expected to aid in suppressing the cellular response. In this case, however, the patient's mucosal lesions and bronchiolitis obliterans were not improved by regular administration of cyclosporin therapy.
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Chika
C
Namba
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Mikiko
M
Tohyama
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Yasushi
Y
Hanakawa
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Masamoto
M
Murakami
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Yuji
Y
Shirakata
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Ehime, Japan.
Takuya
T
Matsumoto
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Ehime, Japan.
Koichiro
K
Suemori
Department of Dermatology, Kurume University School of Medicine, Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan.
Norito
N
Ishii
Department of Dermatology, Kurume University School of Medicine, Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan.
Takashi
T
Hashimoto
Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Koji
K
Sayama
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000175:diagnosis / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007564:Japan; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000188:drug therapy; D008875:Middle Aged; D009092:Mucous Membrane / Q000473:pathology; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D010392:Pemphigus / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab; D016572:Cyclosporine; D003520:Cyclophosphamide
B-cell lymphoma; bronchiolitis obliterans; cyclosporin; mucosal erosions; paraneoplastic pemphigus